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Abstract:  This study explored using a novel diffuse correlation 
spectroscopy (DCS) flow-oximeter to noninvasively monitor blood flow and 
oxygenation changes in head and neck tumors during radiation delivery. A 
fiber-optic probe connected to the DCS flow-oximeter was placed on the 
surface of the radiologically/clinically involved cervical lymph node. The 
DCS flow-oximeter in the treatment room was remotely operated by a 
computer in the control room. From the early measurements, abnormal 
signals were observed when the optical device was placed in close 
proximity to the radiation beams. Through phantom tests, the artifacts were 
shown to be caused by scattered x rays and consequentially avoided by 
moving the optical device away from the x-ray beams. Eleven patients with 
head and neck tumors were continually measured once a week over a 
treatment period of seven weeks, although there were some missing data 
due to the patient related events. Large inter-patient variations in tumor 
hemodynamic responses were observed during radiation delivery. A 
significant increase in tumor blood flow was observed at the first week of 
treatment, which may be a physiologic response to hypoxia created by 
radiation oxygen consumption. Only small and insignificant changes were 
found in tumor blood oxygenation, suggesting that oxygen utilizations in 
tumors during the short period of fractional radiation deliveries were either 
minimal or balanced by other effects such as blood flow regulation. Further 
investigations in a large patient population are needed to correlate the 
individual hemodynamic responses with the clinical outcomes for 
determining the prognostic value of optical measurements. 
© 2012 Optical Society of America 
OCIS codes: (170.0170) Medical optics and biotechnology; (170.3660) Light propagation in 
tissues; (170.3880) Medical and biological imaging; (170.6480) Spectroscopy, speckle. 
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Head and neck cancer accounts for about 3 to 5% of all cancers in the United States [1]. These 
cancers are more common in men and in people over age 50 [2]. More than 90% of head and 
neck cancers are of squamous cell origin that line the mucosal tissues in the head and neck 
area, e.g., oral cavity, tonsils, larynx and hypopharynx [3]. Head and neck cancers very 
commonly spread to the lymph nodes of the neck. Radiation therapy is a principal modality in 
the treatment of head and neck cancers. According to the stage, size, and location of the 
tumors, radiation therapy may be combined with surgery, chemotherapy or both in the 
treatment of this disease [4]. Radiation therapy works by damaging the DNA of cancerous 
cells ultimately resulting in cell death. Radiation can also cause long-term changes in the 
vasculature mediated through inflammatory cytokines and other agents. When using x-ray 
beams for therapy, approximately two thirds of DNA damage is caused by free radical attack 
on the DNA [5]. The efficacy of radiation therapy with x rays is known to be dependent on 
tumor oxygen status. Under hypoxic conditions, the damage to DNA can be repaired more 
readily than under euoxic conditions where the damage is irreversible because of the 
interaction of tissue oxygen with free radicals [6,7]. Many tumors are hypoxic because of the 
high oxygen consumption by tumor cells and/or poor blood flow associated with tumor 
angiogenesis [6]. Studies using polarographic electrode have exhibited an increase of positive 
response to radiation therapy in tumors with high pretreatment oxygenation compared to 
poorly oxygenated tumors [8–12]. However, in these studies some well-oxygenated tumors 
failed to respond while some hypoxic tumors responded well, possibly due to the changes in 
tumor oxygen status during radiation treatment. Recent investigations using polarographic 
electrode, magnetic resonance imaging (MRI), dynamic computed tomography (CT) and 
133Xe clearance method have shown that tumor hemodynamic parameters changed over the 
period of radiation therapy and less-perfused tumors responded poorly [13–18]. Therefore, 
functional assessment of tumor oxygenation and blood flow changes during radiation therapy 
may help understand radiation pathology and holds potential for the prediction of therapy 
outcomes. 
Tumor hemodynamics and metabolism, however, are not routinely measured during 
cancer therapy in clinic due to the lack of appropriate technologies. Several methods exist for 
the measurement of blood oxygenation and flow in tumors. The polarographic electrode 
method provides a point measurement of tumor oxygenation [8–12]. However it is invasive 
and often produces inconsistent results in highly heterogeneous tissues. Imaging modalities, 
such as positron emission tomography (PET) [19,20], dynamic CT [15,17,21,22], functional 
MRI (fMRI) [23] and perfusion MRI [13,16], provide structural and functional information 
about tumors but require large and costly instrumentation which limits their routine use in the 
clinic. Furthermore, these imaging modalities cannot measure tumor response in real time 
when radiation is being delivered into the tumor cells. Doppler ultrasound is a common 
clinical tool for functional measurement of blood flow within large vessels, but cannot probe 
tumor microvasculature [24]. 
Near-infrared (NIR) diffuse optical methods offer a noninvasive, portable, fast and low-
cost alternative for repetitively monitoring tumor hemodynamics at the bedside when therapy 
is administered [25–39]. For example, Sunar et al. [27] have explored the use of a hybrid NIR 
diffuse optical instrument for noninvasive measurements of tumor hemodynamic responses to 
chemo-radiation therapy in patients with head and neck tumors. In their study, tumor blood 
flow and oxygenation were measured right before radiation treatment once a week throughout 
~6 weeks of daily chemo-radiation therapy. Their patients exhibited significant flow and 
oxygenation changes during the first two weeks of treatment, suggesting a potential value of 
hemodynamic measurements for the early evaluation of treatment effects. These results are in 
reasonable agreement with other studies using perfusion MRI [16] and 
133Xe clearance 
method [18]. Furthermore, potential instant changes in tumor hemodynamics during radiation 
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diffuse correlation spectroscopy (DCS) for noninvasively monitoring tumor blood flow 
changes during photodynamic therapy (PDT). They observed a rapid flow decrease in murine 
tumors during PDT light illumination, leading to a poor long-term treatment efficacy. 
Similarly to radiation therapy, sufficient tissue oxygen must be presented during PDT to 
create singlet oxygen that kills tumor cells and vasculatures [25]. These previous results imply 
that continuous monitoring of tumor hemodynamics during radiation delivery may also assist 
in assessing treatment outcomes. 
Very recently, a portable NIR DCS flow-oximeter has been developed and validated in our 
laboratory which can simultaneously measure tissue blood flow and oxygenation [40–43]. The 
present study is designed to test the feasibility of adapting this novel DCS flow-oximeter for 
noninvasive monitoring of tumor hemodynamics during radiation delivery. For this purpose, a 
customer-designed fiber-optic probe connected to the DCS flow-oximeter was placed directly 
on the surface of the radiologically/clinically involved cervical lymph node. The DCS flow-
oximeter, located in the radiation treatment room, was remotely operated by a computer in the 
control room. From the early measurements, abnormal optical signals were observed when the 
optical device was placed in close proximity of the primary x-ray beams. Phantom tests were 
then designed to identify the source of artifacts. Thereafter, the radiation-generated artifacts 
were avoided by moving the optical device away from the primary x-ray beams. With the new 
experimental setup, eleven patients with head and neck tumors were successfully measured. 
To the best of our knowledge, these are the first  noninvasive measurements of tumor 
hemodynamic changes during x-ray radiation delivery. 
2. Methods and materials 
2.1. Patient characteristics and treatment protocol 
Twenty-three patients undergoing chemo-radiation therapy for head and neck tumors 
participated in this study with the signed consents approved by the University of Kentucky 
Institutional Review Board (IRB). Based on the source-detector (S-D) separation of 2.5 cm set 
in our fiber-optic probe (see Section 2.2), we included only Stage III-IVb SCCHN with a 
cervical tumor node larger than 2 cm detected by CT/PET/MRI scan and either clinically 
palpable or ultrasound defined. Patients with supraclavicular adenopathy were not enrolled as 
there was a possibility of the primary origin from other sites in the chest such as lung or 
esophagus. Radiotherapy in combination with traditional chemotherapy was applied on these 
patients. Each patient received daily fractional radiation over ~7 weeks. A total dose of 70 Gy 
was delivered in once daily fractions of 2 Gy. For chemotherapy, the cisplatin was given at 
100 mg/m
2  on Day 1 and Day 22 of radiation. The role of chemotherapy (cisplatin) in 
head/neck cancer is to increase the incidence of double strand breaks (radiosensitization) and 
decrease the incidence of metastatic disease. During radiation delivery, the patient was 
immobilized on the treatment table with pre-molded plastic mask (see Fig. 1a and Fig. 1b). 
Radiation was delivered in the form of high-energy x-ray beams (6 MV) produced by a 
medical linear accelerator (Clinac 21EX, Varian Medical Systems, USA). The x-ray source 
was mounted on the end of an L-shaped gantry that can be rotated in a plane 360° around the 
longitudinal axis of the patient (see Fig. 1a). In this configuration, the x-ray source 
circumscribed a circle having a radius of 100 cm and always pointed toward the longitudinal 
patient axis. This allowed the x-ray beam to be focused to a point in the patient. Seven to nine 
source positions were approximately equally spaced over 360° around the patient. A typical 
treatment required approximately 15 minutes to complete, of which 3 to 4 minutes was actual 
radiation delivery. The radiation treatment consisted of a series of several short x-ray 
exposures (“beam-on”) followed by periods of no radiation (“beam-off”). 
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Fig. 1. A remotely operated DCS flow-oximeter  system for monitoring head/neck tumor 
hemodynamics during radiation delivery. (a) A DCS flow-oximeter was placed away from the 
rotation plane of x-ray beams in the treatment room. (b) A fiber-optic probe connected to the 
DCS flow-oximeter was fixed on the surface of cervical tumor node using a pre-molded plastic 
mask. (c) A computer in the monitoring/control room was used to remotely operate the DCS 
flow-oximeter in the treatment room. 
2.2. DCS flow-oximeter 
Tumor blood flow and oxygenation changes during radiation delivery were monitored by a 
newly developed DCS flow-oximeter once a week over the 7-week treatment period. Details 
about the DCS flow-oximeter (see Fig. 1a) can be found elsewhere [40–43]. Briefly, long-
coherence (>5 meters) NIR light emitted from two laser diodes (785 and 854 nm, ~100 mw, 
Crystalaser Inc., USA) enters the tissue alternately via two 200 µm diameter multimode 
source fibers that are tightly bundled together. The scattered light through the tissue is 
collected at a distance of 2.5 cm from the source fibers using a 5.6 µm diameter single-mode 
detector fiber connected to an avalanche photodiode (APD, PerkinElmer Inc., Canada). The 
APD measures light intensity (photon count rate) fluctuations from a single speckle area [~25 
μm
2  (π  ×  (5.6/2)
2)] on the tissue surface and its output is fed into a correlator board 
(correlator.com, USA) for computing the light intensity temporal autocorrelation function 
[44–46]:  
  ( )
( )
2 2
I r,t I(r,t τ)
g r, τ 
I
⋅+
=    
Here I(r, t) is the detected light intensity at position r and time t,    denotes a time 
average, and τ is the autocorrelation delay time. The electric field temporal autocorrelation 
function G1(r,  τ)  can  be  derived  from  the  measured g2(r,  τ)  using  the  Siegert  relation: 
( )
( )
( )
2
2 1
21 2
G r, τ
g r, τ 1β 1β gr ,   τ
I
= += +  [47]. Here  ( )
( ) 1
1
G r, τ
g r, τ 
I
= is the normalized 
electric field autocorrelation function, and β is a coherent factor depending mainly on the laser 
coherence and detection optics and is inversely proportional to the number of speckle size. 
Considering the two orthogonal polarization modes collected from the single-mode detector 
fiber, the maximum β value should be ~0.5 [48]. When a polarizer is placed in front of the 
detection fiber, a β value of ~1 can be achieved. Note that the biological system studied must 
be assumed ergodic when applying the Siegert relation. The approximation of biological 
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validation studies have shown that DCS flow measurements are in good agreement with other 
microvasculature flow measurement techniques [25,27], suggesting such potential errors are 
not significant. 
The G1(r, τ) satisfies the correlation diffusion equation in highly scattering media [44–46]. 
For semi-infinite homogeneous tissue, the analytical solution of G1(r, τ) is a function of the 
mean-square displacement <Δr
2(τ)> of moving scatterers in tissue (primarily red blood cells). 
For  the  case  of  diffusive  motion,  <Δr
2(τ ) >  =  6 DBτ,  where  DB  is an effective  diffusion 
coefficient of the moving red blood cells. An α term (0 to 1) is added to account for not all 
scatterers in tissue being dynamic and is defined as the ratio of moving scatterers to total 
scatterers (static + dynamic). The combined term, αDB, is referred to as the blood flow index 
in biological tissues and is commonly used to calculate the relative blood flow (rBF) 
compared to the baseline flow index before physiological changes. The αDB and β are derived 
by fitting the measured autocorrelation function to the analytical solution of g2(r, τ). 
The oxygenation information is obtained by recording the light intensities at two 
wavelengths (785 and 854 nm) [40–43]. These two wavelengths were chosen based on the 
lasers available at the time when the instrument was built. Optimization of wavelengths will 
be the subject of future work. The changes of oxygenated hemoglobin concentration (ΔHbO2) 
and deoxygenated hemoglobin concentration (ΔHb) relative to their baseline values before 
treatment are calculated using a “differential pathlength method,” based on the modified Beer-
Lambert Law [49]. The modified Beer-Lambert law incorporates the increased optical 
pathlength due to tissue scattering. A differential pathelength factor (DPF), the ratio of the 
mean photon pathlength to the physical separation of the source and detector, is introduced to 
account for the pathlength increase. The ΔHbO2 and ΔHb are derived from the measured 
changes in light intensities at the two wavelengths which depend on the extinction coefficients 
and DPF values at the corresponding wavelengths. The extinction coefficients and DPF values 
are determined based on the literature [50,51]. 
2.3. Remotely operated optical measurements during radiation delivery 
A customer-designed fiber-optic probe was taped on the surface of the 
radiologically/clinically involved cervical lymph node (see Fig. 1b) using Elastikon tape 
(Johnson & Johnson Inc., USA) for tumor blood flow and oxygenation measurements. The 
optical probe consisted of source and detector fibers (at a separation of 2.5 cm) whose tips 
were bent 90° and held by a soft-foam pad. The nonmetallic optical fibers and the soft-foam 
pad are low-density, low atomic number materials which have negligible attenuation effects 
on the x-ray beam. A standard head/shoulder plastic immobilization mask (WFR/Aquaplast 
Corp., USA) was molded around the pre-positioned optical probe to ensure proper probe 
placement during subsequent treatment sessions (see Fig. 1b). The optical probes and DCS 
flow-oximeter device were kept inside the treatment room during radiation delivery and the 
laptop console was remotely operated by a computer located in the monitoring/control room 
(See Fig. 1c). The two computers worked under the “Remote Desktop Connect” mode in the 
Microsoft Windows Operating System and communicated through the internal network in the 
clinic. Using this real-time monitoring system, the optical measurements can be precisely 
timed with the presence or absence of the x-ray beam. 
From the early optical measurements in some patients, abnormal values of β (>0.5) and 
αDB were observed for some x-ray beam positions. The occurrence of the artifacts depended 
on the angle of the x-ray beams as well as the location of optical device. We suspect that 
scattered x rays were interacting directly with the photodiodes generating spurious signals. 
These signal perturbations were apparently responsible for the measurement artifacts in 
autocorrelation functions. To confirm the source of these artifacts, phantom tests were 
performed (see Section 2.4) under the same radiation conditions used for the patient 
treatments. 
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Tissue-like liquid phantoms have been commonly used for instrument calibration and 
experimental validation of DCS techniques [46,48,52,53]. For this study, the experimental 
phantom was prepared by filling a cylindrical tank with the mixture of distilled water, India 
ink (Black India 44201, Higgins, USA) and Intralipid (Fresenius Kabi, Sweden). India ink 
was used to determine the absorption coefficient µa  while Intralipid provided particle 
Brownian motion (flow) and control of the reduced scattering coefficient µs′. We set µa = 0.12 
cm
−1 and µs′ = 8 cm
−1 at 785 nm to mimic the property of real tissues [53]. The Intralipid 
phantom provided a homogeneous tissue model with controlled optical properties and 
constant particle flow, which should not be changed by the x rays. In addition, using tissue 
phantom can avoid some other potential artifacts (e.g., motion artifacts) that may occur in the 
patient measurements [54]. 
The set up for the phantom test was similar to that for patient measurements shown in Fig. 
1, except that the patient was replaced with the liquid phantom contained by a cylindrical 
tank. During the beam-on interval, the x-ray beam was turned on continually and rotated 
around the liquid phantom over 360 degrees. The fiber-optic probe was secured in contact 
with the phantom surface using a customer-designed holder. The DCS flow-oximeter device 
was set up in two locations inside the treatment room; one was close to the x-ray beam plane 
so that the optical device was subjected to a significant fluence of scattered x rays and another 
was several meters away from the x-ray beam plane. This arrangement approximated the two 
extreme positions in a typical patient treatment delivery. The radiation beam energy (6 MV) 
used for the phantom tests was same for the patient treatments (see Section 2.3). 
2.5. Optical data analysis and presentation 
Although 23 patients were measured, 12 patient data were excluded for data analysis as their 
optical measurements were thought to be contaminated by scattered x rays. The data exclusion 
was based on the abnormal β value (>0.5). Details about the tumors, optical measurements 
(without artifacts), and treatment outcomes of the eleven male patients aged 53 to 74 years are 
listed in Table 1. Patients with unknown primary cancers (#6 and #8) were treated as 
head/neck cancers based on nodal stage of disease with primary origin suspected in the tonsil 
or the base of tongue. The Response Evaluation Criteria in Solid Tumors (RECIST) [55] were 
used to define the tumor response to chemo-radiation therapy. For example, a complete 
response (CR) indicates the disappearance of all target lesions and a partial response (PR) 
represents at least a 30% decrease in the sum of the longest diameter of target lesions. Note 
that even though some lymph nodes persisted 12 weeks post-treatment (see the post-radiation 
tumor volumes of Patients #2, #4, #7 listed in Table 1), they were physiologically normal; the 
PET was not showing activity and no further treatment was needed. The metastatic 
adenopathy in Patient #4 was in the upper neck. The optical measurements over the entire 
treatment course were not always available for each individual due to the patient related 
events such as side effects of treatment, fatigue, non-compliance with chemo-radiation 
regimen or due to time constraints of obtaining measurements and modification of treatment 
schedules as a consequence of temporary breakdown in radiation therapy equipment. 
Since DCS flow signals are not sensitive to variation in the wavelength [40,53], blood 
flow data obtained from one wavelength (785 nm) are  presented in this study. The time 
courses of blood flow and oxygenation data are normalized to their baseline values right 
before the radiation delivery, respectively. More specifically, rBF represents the blood flow 
change relative to its baseline (assigned to be “1”), and the ΔHbO2 and ΔHb are the dynamic 
changes in oxygenated and deoxygenated hemoglobin concentrations relative to their 
baselines  (assigned  to  be  “0”).  The  rBF,  ΔHbO2  and  ΔHb  during  the  fractional  radiation 
deliveries (beam-on intervals) or between the fractional deliveries (beam-off intervals) are  
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a 
Pat. 
No. 
Primary 
site  TNM 
Optical measurements over the 
7-week treatment period 
Tumor node 
volume 
(cm
3)  Tumor responses 
1  2  3  4  5  6  7 
Pre-
RT 
Post-
RT  Primary  LN  Overall 
1  Tonsil  T2N2cM0  A  A  A  A           34  6  CR  CR  CR 
2  BOT  T3N2cM0  A  A                 57.9  35  PR  CR*  PR 
3  BOT  T1N2bM0  A  A                 27  1.32  CR  CR  CR 
4  BOT  T2N2cM0  A                    90  27  CR  CR 
CR but 
metastasis 
developed 
5  Tonsil  T1N2bM0  A                    24  1.3  CR  CR  CR 
6  Unknown  TxN3M0  A  A  A  A  A  A  A  18  0  CR  CR  CR 
7  BOT  T2N2cM0  A  A  A  A  A  A     28  13  CR  CR  CR 
8  Unknown  TxN2bM0  A  A  E  E  E  A  A  14.6  1  CR  CR  CR 
9  Larynx  T4aN2aM0  A  A  A              44.1  1  CR  CR  CR 
10  BOT  T3N2cM0  A  A     A  A  A  A  14  0  CR  CR  CR 
11  Larynx  T3N2cM0  A  A  A  A    A  A  16  0  CR  CR  CR 
aAbbreviations: Pat. = Patient, BOT = Base of Tongue, TNM = Tumor, Node, and Metastasis stage, RT = Radiation 
Therapy, A = Data Available, E = Data Excluded (unstable baseline of optical measurements), LN = Lymph Node, 
CR = Complete Response, PR = Partial Response 
*indicates that the patient underwent a neck dissection after Chemo-RT and had persistent radiological finding 
suspicious for persistent disease but the pathology specimen did not show viable tumor. 
averaged separately for assessing the instant response to radiation delivery in each individual. 
The averaged hemodynamic changes over patients at multiple weeks generate the dynamic 
variation trends of rBF,  ΔHbO2 and  ΔHb  over  the  7-week treatment period. The average 
hemodynamic responses over subjects are presented as means ± standard errors (error bars) in 
figures. For statistical analyses, significance is tested using the paired t-test. The criterion for 
significance is p < 0.05.  
Results 
3.1. Phantom tests 
Figure 2 shows the optical measurement data at the wavelength of 785 nm from the phantom 
test when the DCS flow-oximeter was placed close to the x-ray beam plane. During the test,  
   
Fig. 2. The phantom test results to verify the source of optical measurement artifacts. (a) Two 
autocorrelation curves (g2) were collected at the time points of 117 (contaminated) and 55 (not 
contaminated) (sec), respectively. The measured autocorrelation curve (empty  circles) was 
contaminated by scattered x rays, resulting in an abnormal increase in β. (b) The appearance of 
abnormal increases in β (>0.5, empty circles) depended on the direction/angle of the radiation 
beam that rotated 360° around the phantom. (c) The x-ray beam induced abnormal increases in 
relative flow (empty circles) derived from the autocorrelation curves. (d) The x-ray beam 
induced slight increases in detected photon count rate ( × 10
3 photons/s) (empty circles). 
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beam was directed toward the optical device, abnormal correlation curves (g2) were obtained 
(see an example shown in Fig. 2a) leading to large increases in β (>0.5, see Fig. 2b) and αDB 
(see Fig. 2c) as well as slight increases in detected photon count rate (see Fig. 2d). When the 
DCS flow-oximeter device was moved away from the rotation plane of the x-ray beams, the 
optical measurements became normal for all beam directions. Similar results at the 
wavelength of 854 nm were also found during the phantom test (data are not shown). Notice 
that  in  this  study  β  (Fig. 2b)  and  αDB  (Fig. 2c) were derived by fitting the measured 
autocorrelation function curve g2 (Fig. 2a), as mentioned in Section 2.2. However, β can be 
also estimated based on the Siegert relation using the measured g2 data (Fig. 2a) at earliest τ 
and letting the normalized autocorrelation function g1 ≈1, i.e., β = g2(τ ≈0) - 1 (Fig. 2b) [53]. 
 
Fig. 3. The in vivo measurement results for the investigation of optical measurement artifacts 
induced by scattered x rays. (a) Three autocorrelation curves (g2) were collected at the time 
points of 417 (contaminated), 99 (slow flow), and 724 (fast flow) (sec), respectively. Similar to 
the phantom test results (see Fig. 2a), scattered x rays contaminated the measured 
autocorrelation curves (empty circles). For the data without contaminations (solid circles), the 
decay rate of autocorrelation curves depended on the level of blood flow; g2 decayed faster 
when blood flow was faster (black solid circles). As expected, β (can be estimated using the 
measured g2 data at earliest τ) was independent of blood flow changes when there were no x-
ray induced artifacts. (b) Scattered x rays created abnormal increases in β (>0.5, empty circles) 
depending on the direction/angle of radiation beam. (c) The x-ray beam introduced abnormal 
increases in blood flow (empty circles) derived from the autocorrelation curves. (d) The x-ray 
beam induced minor variations in detected photon count rate ( × 10
3 photons/s) (empty circles). 
3.2. In vivo optical measurements 
Artifacts were also observed in some optical measurements of tumor hemodynamics for some 
x-ray beam directions. Figure 3 shows the typical contaminated optical data measured at the 
wavelength of 785 nm during a fractional radiation treatment. Similar to the phantom test 
results, abnormal correlation curves as well as the increases in β (>0.5) and blood flow index 
(αDB) were observed (see Fig. 3a, 3b, and 3c) when the optical device was subjected to 
significantly scattered x rays. This effect also induced minor variations in detected photon 
count rate (see Fig. 3d). Similar artifacts were also observed at the wavelength of 854 nm 
(data are not shown). These results are consistent with the findings from the phantom tests 
(see Section 3.1). 
After identifying the source of radiation artifacts, we modified the optical measurements to 
minimize these effects. A new fiber-optic probe was constructed using the source and detector 
fibers with a length longer than 5 meters. The optical device connected with the new probe 
was placed approximately 3 meters from the rotation plane of the x-ray beams. The longer 
fiber cable allowed the DCS detector assembly to be moved much further away from the 
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Thereafter, using the new measurement configuration no artifacts (i.e., abnormal β and αDB) 
were observed in the optical data. Figure 4 shows the typical responses of rBF, ΔHb and 
ΔHbO2  during radiation delivery measured from one patient (#6) at two different weeks 
(Week 1 and Week 4). The  values of  β throughout the  treatment period  were stable  and 
approximately equal to 0.5 (see Fig. 4a and Fig. 4b), indicating no artifacts involved in the 
optical measurements. A gradual increase in rBF was observed at Week 1 (see Fig. 4c), but 
not at Week 4 (see Fig. 4d). Variations in ΔHb (see Fig. 4e and Fig. 4f) and ΔHbO2 (see Fig. 
4g and Fig. 4h) were also found at both weeks. There were no obvious differences in tumor 
hemodynamic responses (i.e., rBF, ΔHb and ΔHbO2) between the intervals of x-ray beam-on 
and beam-off. 
 
Fig. 4. The in vivo optical measurement results without x-ray induced artifacts during radiation 
delivery from one patient (#6) at Week 1 (left panel) and Week 4 (right panel). As expected, β 
((a) and (b)) was stable throughout the fractional radiation deliveries and independent of blood 
flow changes. The typical responses of rBF ((c) and (d)), ΔHb ((e) and (f)), and ΔHbO2 ((g) 
and (h)) were continuously monitored by the DCS flow-oximeter during radiation delivery. 
3.3. Averaged hemodynamic responses over patients 
Figure 5 shows the averaged dynamic changes in rBF, ΔHb, and ΔHbO2 over the 11 patients 
at different weeks. The numbers of patients with valid optical data (without artifacts) are 
labeled at each week in Fig. 5a. On average, there were no significant differences in most of 
the measured hemodynamic variables (i.e., rBF, ΔHb, ΔHbO2) between the intervals of x-ray 
beam-on and beam-off, except that a small but significant difference in ΔHbO2 (−0.29 ± 0.12 
µM, p = 0.03) was observed between the x-ray beam-on and beam-off at Week 1 (see Fig. 5c). 
However, the changes in ΔHbO2 during radiation delivery at Week 1 for both beam-on and 
beam-off were insignificant compared to their baseline values, respectively. As a result, the 
averaged ΔHbO2 changes including both beam-on and beam-off data at Week 1 were also 
insignificant. Therefore, the hemodynamic changes were believed to be induced by an 
accumulated effect of the fractional radiation dose over the entire period of radiation delivery. 
Thus,  we calculated the individual  means of hemodynamic responses (i.e., rBF, ΔHb and 
ΔHbO2) over the entire course of radiation treatment including both beam-on and beam-off 
intervals. The calculated average hemodynamic results over the 11 patients are listed in Table 
2. Although variations in rBF during radiation delivery were observed over the 7-week 
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compared to its baseline before treatment. By contrast, the variations in both ΔHb and ΔHbO2 
over the treatment periods were not statistically significant. 
 
Fig. 5. The averaged dynamic changes in rBF (a), ΔHb (b) and ΔHbO2 (c) over the 11 patients 
at different weeks. Data obtained during the fractional radiation deliveries (beam-on intervals) 
or between the fractional deliveries (beam-off intervals) were averaged separately. A small but 
significant difference in ΔHbO2 (−0.29 ± 0.12 µM) was observed between the x-ray beam-on 
and beam-off at Week 1 (* represents p = 0.03). 
Table 2. Overall changes (mean ± standard error) in rBF, ΔHb and ΔHbO2 over 11 
patients at different weeks 
Week  1  2  3  4  5  6  7 
No. of patients  11  9  5  5  3  5  4 
rBF  1.11 ± 
0.03** 
1.04 ± 
0.03 
1.07 ± 
0.06 
1.03 ± 
0.05 
1.13 ± 
0.12 
1.05 ± 
0.04 
1.06 ± 
0.04 
ΔHb (µM)  −0.96 ± 
1.66 
0.91 ± 
1.00 
1.82 ± 
0.58 
1.77 ± 
0.97 
0.05 ± 
1.10 
0.71 ± 
0.92 
−0.21 ± 
1.02 
ΔHbO2 (µM)  −0.44 ± 
0.70 
0.00 ± 
0.69 
−0.36 ± 
1.07 
−0.97 ± 
0.87 
0.67 ± 
0.54 
1.66 ± 
0.85 
1.46 ± 
2.14 
**represents p = 0.003. 
4. Discussion and conclusions 
Previous studies have shown that the quantification of pretreatment tumor hemodynamic 
status holds potential for the prediction of radiation treatment outcomes [8–12]. Real-time 
monitoring of tumor hemodynamic changes during radiation delivery may provide additional 
information for better evaluation of treatment effects. Such information may be useful for 
pretreatment planning or early adjustment of treatment modalities. For example, if correlated 
with poor treatment outcomes, highly hypoxic tumors identified before treatment may be 
directly referred for surgery instead of radiotherapy. Non-responders to  radiotherapy, if 
identified by early tumor hemodynamic responses (e.g., within the first two weeks of 
treatment), may be administered alternative neoadjuvant therapy and/or referred for surgery. 
Such management can avoid delays in the selection of appropriate treatment modalities, thus 
potentially reducing patient complications due to radiotherapy that is either unnecessary or not 
efficacious. 
However, currently available imaging modalities (e.g., fMRI, PET and Dynamic CT) 
cannot be used at the bedside of clinical treatment rooms to perform real-time monitoring 
during radiation delivery. Although NIR diffuse optical techniques have been used as bedside 
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inside the radiation treatment room. The challenges to adapt the optical techniques for use 
during radiation delivery include installing the optical probe properly on the surface of tumor 
node, operating the optical device from a separated control room, and avoiding the potential 
interference between the scattered x rays and optical measurements. In the present study 
several crucial steps were taken to adapt the DCS flow-oximeter for the use of monitoring 
tumor blood flow and oxygenation during radiation delivery. A pre-molded plastic mask was 
made to hold the optical probe in a proper contact with the tumor nodal mass (see Fig. 1a and 
Fig. 1b) throughout the treatment period for reducing the motion artifacts to optical 
measurements. Two computers located separately in the treatment and control rooms 
communicated through the internal network, enabling to remotely operate the DCS flow-
oximeter (see Fig. 1c). Finally, tissue phantom tests were conducted to determine the source 
of  optical  measurement  artifacts  (i.e.,  abnormal  β  and  αDB) observed in the patient 
measurements during radiation delivery. 
As  described  early  in  Section  2.2,  β  depends  mainly  on  the  detection  optics,  and  the 
maximum  β  value  should  be  ~0.5  when  using  a  single-mode fiber to detect the speckle 
fluctuations [48]. However, abnormal high values of β (>0.5) were observed during radiation 
delivery in both phantom (see Fig. 2) and patient (see Fig. 3) measurements when the optical 
device was placed close to the rotation plane of x-ray beams. When the DCS flow-oximeter 
device was moved away from the x-ray beams, the optical measurements became normal 
throughout the entire treatment period (see Fig. 4). These findings suggest that the observed 
artifacts were generated by the scattered x rays interacting directly with the optical detector 
and they can be eliminated by simply moving the optical device (detector) away from the 
radiation beams. 
After moving the optical device out of the x-ray beams, we have successfully collected 
valid optical data (without artifacts) from 11 patients during x-ray delivery. Large inter-patient 
variations in tumor hemodynamic responses were observed during radiation delivery (see the 
large error bars in Fig. 5). On average (see Table 2), a significant increase in tumor blood flow 
during radiation delivery was observed at the first week of treatment, which may be a 
physiologic response to hypoxia created by radiation oxygen consumption. Similar increases 
in blood flow were previously observed in tumors during the early period of PDT delivery 
[25]. This regulation ability in blood flow seemed to decline with the progress of weekly 
treatments. Interestingly, only small and insignificant changes were found in tumor blood 
oxygenation (ΔHb and ΔHbO2) during radiation delivery over the 7-week treatment period 
(see Table 2). The absence of substantial tumor oxygenation changes suggested that oxygen 
utilizations in tumors during the short period of fractional radiation deliveries (3 to 4 minutes) 
were either minimal or balanced by other effects such as blood flow regulation. Clarification 
of the reasons for limited oxygenation changes during radiation delivery will require separate 
investigations. Oxygenation changes during radiation therapy may be due to the reassortment 
of the cells in the cell cycle, revascularization, repopulation of the tumor cells and cell kill. As 
these issues were not being measured it is outside the purview of the present study. 
Although the present investigation has yielded preliminary findings, some study 
limitations need to be noted. Firstly, the continuous-wave (CW) DCS flow-oximeter measures 
only the relative changes of tumor hemodynamics during radiation delivery. It is surely 
possible that the absolute baseline values of tumor hemodynamics are different among 
patients before treatment [53] and can be changed by the fractional radiation treatments over 
the treatment period [27]. Furthermore, the CW DCS flow-oximeter used in this study cannot 
quantify tissue scattering changes during treatment. However, results from the previous study 
[27] using a frequency-domain device showed that only ~5% changes in tumor scattering 
coefficient (µs′) were observed over several weeks of fractionated radiation treatment. 
According to our recent study on the influences of µs′ to DCS measurement [53], this small 
amount of µs′ variation should not significantly affect our flow results. The second limitation 
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over the entire course of treatment (see Table 1). A large pool of patients and optical data 
would increase the statistical power of measurement results. Lastly, the treatment outcomes 
from the patients need to be correlated with tumor hemodynamic responses to determine the 
prognostic value of optical measurements. However, all eleven patients involved in this study 
demonstrate consistent treatment outcomes (i.e., a complete response to radiation treatment) 
in the measured cervical lymph nodes (see Table 1), making it impossible to investigate the 
correlations between tumor hemodynamic responses and clinical outcomes. To overcome 
these limitations of the present study, we have recently combined the DCS device with a 
commercial frequency-domain tissue-oximeter (Imagent, ISS Inc. USA) that can measure the 
absolute values of tumor optical properties and tumor oxygenation [53]. We will use this 
hybrid instrument to quantify the absolute values of tumor hemodynamics during radiation 
treatment. More patients are being recruited and clinical outcomes continue to be collected. 
Although there is much work to be done, our pilot study results suggest that tumor 
hemodynamic changes during radiation delivery can be optically detected using the DCS 
flow-oximeter without being overly burdensome on patients. The unique remotely operated 
optical system developed in this study has potential to be used in other therapeutic/diagnostic 
rooms (e.g., CT) where operators are not allowed to stay. It is our hope that real-time 
monitoring of tumor hemodynamic changes during radiation delivery integrated with the 
pretreatment absolute measurements of tumor blood flow and oxygenation will provide best 
information for the early prediction of cancer treatment outcomes. 
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